Literature DB >> 8827975

The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines.

J B Robbins1, R Schneerson, P Anderson, D H Smith.   

Abstract

The development of Haemophilus influenzae type b (Hib) conjugate vaccines has led to the virtual elimination of systemic infections caused by that pathogen, has provided insights into the pathogenesis of and immunity to other capsulated bacteria, and has contributed to the development of new vaccines. Meningitis, a common and serious infection of children, and other infections caused by Hib have been virtually eliminated in countries that have achieved widespread vaccination with Hib conjugates, including the United States, Canada, the United Kingdom, Iceland, Scandinavia, France, and Germany. Hib conjugates have also been shown to be highly effective in developing countries. The principles derived from the use of these vaccines, along with studies of other capsulated pathogens, should allow the rapid inclusion of new polysaccharide-based conjugates into routine vaccination schedules of infants, and should help to realize further reductions in serious systemic infectious diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827975     DOI: 10.1001/jama.276.14.1181

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  35 in total

1.  Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.

Authors:  H K Guttormsen; A H Sharpe; A K Chandraker; A K Brigtsen; M H Sayegh; D L Kasper
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B.

Authors:  Y Sun; M K Park; J Kim; B Diamond; A Solomon; M H Nahm
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

3.  Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1.

Authors:  V Pozsgay; C Chu; L Pannell; J Wolfe; J B Robbins; R Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

4.  Changing Epidemiology of Bacterial Meningitis in the United States.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

Review 5.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

6.  Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom.

Authors:  J McVernon; M E Ramsay; A R McLean
Journal:  Epidemiol Infect       Date:  2007-08-03       Impact factor: 2.451

7.  The tuberculosis epidemic. Scientific challenges and opportunities.

Authors:  A M Ginsberg
Journal:  Public Health Rep       Date:  1998 Mar-Apr       Impact factor: 2.792

Review 8.  Clustered carbohydrates in synthetic vaccines.

Authors:  Francesco Peri
Journal:  Chem Soc Rev       Date:  2012-12-18       Impact factor: 54.564

Review 9.  Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection.

Authors:  Malcolm J M Darkes; Greg L Plosker
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

10.  Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.

Authors:  Zhigang Jin; Chiayung Chu; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.